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Abstract
Purpose: The objective of this study was to perform a preliminary evaluation of the ocular and systemic safety 
of calcium formate, a dietary calcium supplement for prevention and management of osteoporosis. Although 
formate is an endogenous product of metabolism, high concentrations are associated with toxicity during meth-
anol overdose.
Methods: In this prospective clinical trial, 12 healthy women ingested calcium formate (1,300 mg) three times 
a day for 14 days. Study evaluations included physical and ocular examination, extensive laboratory testing, 
serum calcium and formate levels, Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, color 
vision, visual fi elds, visual evoked potential (VEP), and full-fi eld, pattern, and multifocal electroretinograms 
(MERG).
Results: The mean baseline serum level of formate was 0.572 ± 0.06 mM. Peak serum levels and fi nal serum for-
mate did not differ signifi cantly from baseline. The fi nal concentration was 0.582 ± 0.091 mM. Accumulation of 
serum formate did not occur. There was also no evidence of toxicity with calcium formate ingestion. All exami-
nations and tests remained normal, including optic nerve and retinal function. Three subjects had mild transient 
symptoms attributable to any calcium formulation.
Conclusions: Calcium formate is highly bioavailable and well-tolerated. Serum formate remained at basal levels 
and did not accumulate with repeated dosing. Systemic and ocular safety was demonstrated by objective test-
ing. Given its high oral bioavailability, calcium formate may be a good choice for calcium supplementation in the 
prevention and management of osteoporosis. Further study will be needed to evaluate its long-term safety in a 
larger group of subjects representing more varied age, health, dietary, and nutritional status.
Introduction
Calcium supplementation is useful in the prevention of osteoporosis, a disorder of bone in which bone min-
eral density is reduced and bone microarchitecture is altered 
leading to bone fragility and a predisposition to fractures.1 
The underlying mechanism in osteoporosis is an imbalance 
between bone resorption and bone formation, both of which 
are heavily infl uenced by nutritional and hormonal factors.2 
Because of its hormonal component, menopausal (ie, estro-
gen defi cient) women comprise the largest group of indi-
viduals suffering from osteoporosis. In the United States, 
>10 million people have osteoporosis and 34 million have 
osteopenia, or low bone mass, the precursor condition for 
osteoporosis.3 Osteoporosis is responsible for millions of 
fractures annually, primarily involving the lumbar verte-
brae, hip, and wrist. The incidence increases with age and 
the 1-year mortality rate following hip fracture is ~20%.
Dietary calcium supplementation, which has been found 
to increase bone density and diminish the risk of associ-
ated fractures, is an important aspect of the prevention and 
management of osteoporosis.4–7 Calcium formate is a novel 
dietary calcium supplement8 with superior bioavailability 
compared with the most commonly used supplements such 
as calcium carbonate and calcium citrate.9 Although formate 
is a normal endogenous metabolite, sustained high concen-
trations of serum formate, such as those occur in cases of 
poisoning by methyl alcohol (wood alcohol), can be toxic, 
especially to the retina and optic nerve.10–12 These effects 
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photographs were evaluated by masked graders for the pres-
ence of retinal edema, hemorrhage, and optic nerve abnor-
mality. Color vision was assessed with the FM-100 Hue test. 
Visual fi eld testing utilized the automated standardized 
Humphrey 24-2 using the Swedish Interactive Threshold 
Algorithm.
Electroretinographic (ERG) testing conformed to the stan-
dards set forth by the International Society for the Clinical 
Electrophysiology of Vision. Testing was performed with 
a UTAS-3000 (LKC Instruments, Gaithersberg, MD) visual 
electrodiagnostic device. ERG testing obtained intensity ver-
sus response functions under dark-adapted (scotopic) and 
light-adapted (photopic) conditions to test retinal function.
The pattern ERG (PERG) assessed ganglion cell func-
tion. Recording was performed with chessboard pattern 
stimuli that exchange black and white squares at a rate of 
2 Hz. The peak latency and amplitude of response waves 
were determined. VEPs were recorded from scalp electrodes 
to evaluate optic nerve function, measuring the latency and 
amplitude of the positive wave near 100 ms. Baseline and 
follow-up tests were compared by time group and for indi-
vidual subjects across time. The selection of sample size was 
based on the VEP test, with normal variation being ±5 ms, 
and a delay of 8 ms considered defi nitely abnormal. Having 
12 subjects allowed a 90% power to detect a signifi cant dif-
ference in this critical test with P < 0.05.
Multifocal ERG (MERG) was performed to provide addi-
tional topographic information regarding retinal func-
tion.16,17 This test used the Visual Evoked Response Imaging 
System (version 4.9, EDI Inc., CA) with dilated pupils. Both 
eyes were tested simultaneously. The 103 fi rst-order kernel 
MERGs were reduced to six waveforms that were the average 
of six concentric rings from the fovea. The peak latency and 
amplitude of the response waves were scored using an auto-
mated routine written in Matlab™ (Natick, MA). Averages 
of the six rings across the 12 subjects were compared across 
baseline, postdose day 3 and day 15 using a multivariate 
ANOVA. Individual comparison for each subject in all rings 
was also performed to determine whether there were any 
signifi cant departures from baseline responses.
The effect of calcium formate ingestion on each electro-
physiology test was evaluated by determining means and 
confi dence intervals and comparing each time point of test-
ing with the baseline values.
Results
Twelve adult females participated in the study. Their 
mean age was 41 (21–60 years), and mean BMI was 24.3 ± 
2.46. They were free of systemic disorders that could poten-
tially affect calcium absorption or underlying serum calcium, 
such as hyperparathyroidism, bone disease, and intestinal 
malabsorption. No subject had conditions that could be 
exacerbated by calcium intake, such as kidney stones. No 
subject was pregnant. At no time during the study or the 
week preceding it did any subject ingest vitamin or mineral 
supplements or other medications that could affect calcium 
or vitamin D metabolism.
Subjects were fully compliant with the regimen of ingest-
ing 1,300 mg of calcium formate three times a day for 14 con-
secutive days. There were no serious adverse events noted 
by history, examination, laboratory tests, or tests of visual 
function. On two occasions, one subject noted mild bloating 
manifest as reductions in electroretinogram and visual 
evoked potential (VEP) responses.13,14
In view of its potential use as a dietary supplement, the 
current study was designed to evaluate the safety of daily 
ingestion of calcium formate and to determine if serum for-
mate accumulates with repeated dosing. The safety evalua-
tion included sensitive objective testing of retinal and optic 
nerve function.
Methods
Twelve healthy adult females participated in this pro-
spective open-label clinical trial (NCT00204893). The proto-
col adhered to the tenets of the Declaration of Helsinki and 
was approved by the University of Wisconsin Institutional 
Review Board. Signed written informed consent was 
obtained. A safety board was convened to review potential 
adverse events. Subjects were monitored throughout their 
participation for adverse events and adherence to proto-
col. A tablet count was performed upon completion of the 
study.
Inclusion criteria included: (1) age between 19 and 65; 
(2) body mass index between 18 and 27; (3) normal physi-
cal examination and normal electrocardiogram; (4) normal 
ocular examination and normal assessment of function; (5) 
normal clinical laboratory tests; (6) use of two forms of con-
traception, or postmenopausal status for 12 months prior to 
study entry, or surgical sterility, and negative serum preg-
nancy test. Exclusion criteria were: (1) prior history or cur-
rent fi nding of signifi cant ocular abnormality such as optic 
nerve disease, glaucoma, or retinal disease; (2) ocular sur-
gery within 6 months of study entry; (3) abnormality in 
screening tests of visual function.
Subjects had baseline examination and testing followed 
by evaluations on days 1, 2, 3, 8, and 15. Evaluations included 
full physical examination, ECG, testing of respiratory func-
tion with peak fl ow meter and forced expiratory velocity, 
assessment of pupillary responses, dilated ocular examina-
tion, and fundus photographs. Blood samples were obtained 
at baseline and day 15 for CBC, PTH, thyroid status, total 
calcium, ionized calcium, formate, electrolytes, liver func-
tion, glucose, amylase, total protein, albumin, BUN, and cre-
atinine. Serum calcium was tested on selected visits, prior 
to the fi rst dose of the day. Tests of visual function included 
visual fi eld, color vision test, full-fi eld ERG, pattern ERG, 
multifocal ERG, fl ash VEP, and pattern-reversal VEP.
Each subject ingested 1,300 mg of calcium formate 
[Ca(HCO2)2] three times a day for 14 days (total daily dose = 
3,900 mg of calcium formate = 1,200 mg of elemental calcium 
+ 2,700 mg of formate). Serum formate concentrations were 
obtained from venous blood samples. Centrifuged superna-
tant was deproteinized by adding 30 μL of 7.5% ZnSO4 and 
30 μL of 0.4 N NaOH per 100 μL of serum followed by further 
centrifugation. Formate concentrations were determined on 
this supernatant using the fl uorometric assay of Makar and 
Tephly.15 To test for accumulation of serum formate, morn-
ing fasting blood samples were obtained at screening and 
prior to the fi rst dose on study days 1, 2, 3, 8, and 15. Blood 
samples for peak serum formate were obtained 40–60 min 
after ingestion of the second dose on days 1, 2, 3, and 8.
Visual acuity testing was performed with Early Treatment 
Diabetic Retinopathy Study (ETDRS) refraction and ret-
roilluminated Ferris-Bailey charts. Stereoscopic fundus 
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(P = 0.268). When comparing mean peak serum formate at 
different time points, a signifi cant difference is found on day 
1 with a mean concentration of 0.625 mM (P = 0.01) and day 
3 with a mean concentration of 0.625 mM (P = 0.03) com-
pared with the screening value. These values are not signif-
icantly different from the baseline value (day 1, predosing). 
Comparing trough and peak values for each testing day, 
there is signifi cant elevation on day 1 (P = 0.03) and day 2 
(P = 0.04), but not for day 3 (P = 0.19) and day 8 (P = 0.96). 
However, these differences in serum formate are very small 
and clinically insignifi cant. Overall, the results demonstrate 
that despite the administration of 1,300 mg of calcium for-
mate three times per day, the concentration of serum for-
mate remained clinically stable, with no accumulation over 
time and no signifi cant elevation beyond the basal levels 
obtained prior to ingestion.
The physical examination remained unchanged in all sub-
jects, including neurological vitals and pupillary response 
to light. Blood pressure demonstrated a slight decrease but 
this was not statistically signifi cant, with baseline blood 
pressure of 117 ± 15.1 systolic and 75.3 ± 9.7 diastolic versus 
a mean of 111 ± 14.5 systolic (P = 0.06) and 71.7 ± 9.0 dia-
stolic at day 15 (P = 0.12).
The ocular examination was normal in all subjects with 
the exception of one with small macular drusen. All subjects 
had normal visual acuity and visual function testing at base-
line, with no deterioration noted as a group or in any indi-
vidual when comparing their results to baseline. Masked 
assessment of fundus photographs found no changes in 
retinal or optic nerve appearance. The only notable fi nd-
ing when comparing the baseline and fi nal visits was a 
slight improvement in ETDRS visual acuity from 87.92 ± 5.9 
to 90.5 ± 6.5 letters in the right eye and from 89.0 ± 4.0 to 
91.4 ± 4.0 letters in the left eye (P = 0.007). Color vision test-
ing with the FM-100 Hue test found an average of 27.3 errors 
(22.6 SD, P = 0.027) on day 15, compared to the initial result 
of 37.8 errors (17.4 SD) at screening. These color vision results 
are within the normal range at both time points.
Functional assessment of the optic nerve included 
Humphrey 24-2 visual fi elds and VEP. The mean defect at 
baseline was −1.54 (SD 1.8) for the right eye and −1.36 (SD 1.8) 
for the left eye, with follow-up results of −1.3 (SD 1.7) for the 
right eye and −1.34 (SD 1.4) for the left eye (P = 0.33). The pat-
tern standard deviation remained similarly unchanged. The 
latency and amplitude of the VEP were normal for all subjects 
at baseline and showed no signifi cant changes for all sub-
sequent testing points. At screening the combined latency 
for both eyes was 175.3 ± 14.1 ms versus 174.5 ± 13.9 ms on 
day 2 at peak serum level (P = 0.7), and 183.6 ± 21.0 ms on 
day 15 (P = 0.1). The combined amplitude for both eyes was 
17.4 μV (95% CI 13.1–21.7) at screening versus 16.2 μV (95% CI 
12.7–19.8) on day 2 (P = 0.5), and 18.8 μV (95% CI 14.5–23.2) 
on day 15 (P = 0.2).
Functional assessment of the retina included full-fi eld and 
multifocal ERG, as well as pattern ERG to evaluate ganglion 
function. PERG amplitude for both eyes combined measured 
7.7 ± 6.19 μV at baseline versus 5.34 ± 2.44 μV (P = 0.43) on 
fi nal assessment, while latency measured 77.2 ± 12.3 ms at 
baseline versus 69.3 ± 16.7 ms (P = 0.21) on day 15. Despite 
the apparent decrease in mean amplitude and contradictory 
improvement in latency, the results are not statistically dif-
ferent due to broad standard deviation. Full-fi eld ERG test-
ing (Fig. 2) found no evidence of signifi cant change in retinal 
and abdominal cramping 30 min after ingestion of the cal-
cium supplement. The episodes resolved quickly with eating 
and did not lead to discontinuation of the supplement. One 
subject noted two brief episodes of increased perspiration. 
Another complained of minor headache on two occasions, 
unrelated temporally with supplement ingestion.
Laboratory evaluations performed to assess subjects for 
underlying abnormality prior to enrollment were repeated 
during the study. Assessment of liver, kidney, pancreas, thy-
roid, parathyroid, and electrolyte status found one subject 
with mild hypothyroid status at baseline and no subsequent 
change. All other tests remained essentially unchanged 
from baseline in all other subjects.
Serum calcium remained stable through the study. At 
baseline, the mean serum calcium was 9.46 ± 0.27 mg/dL 
(9.0–9.9). At day 15, the mean serum calcium was 9.46 ± 0.31 
mg/dL (8.9–9.9), demonstrating no signifi cant change, 
P = 0.92; ionized calcium remained similarly stable (data not 
shown). This is consistent with numerous studies indicat-
ing that oral calcium supplements rarely produce observable 
alterations in serum calcium levels due to the rapid ability 
of the body to sequester exogenous calcium entering the 
bloodstream, thus maintaining serum calcium within nor-
mal levels.9
Serum formate concentration was evaluated repeatedly 
to determine if toxic levels were reached and whether accu-
mulation occurred with daily ingestion (Fig. 1). At screen-
ing, the mean basal serum formate level was 0.539 ± 0.06 
mM (95% CI 0.497–0.580). Baseline serum formate, prior to 
ingestion of supplements, demonstrated a slightly higher 
mean concentration of 0.572 ± 0.06 mM (95% CI 0.532–0.613). 
On the morning of day 15, the mean serum formate level 
was 0.582 ± 0.091 mM (95% CI 0.521–0.642), with no signif-
icant difference between this value and the screening level 
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FIG. 1. Serum formate concentrations determined prior 
to and throughout the 14-day study. The concentrations 
observed at screening (S) do not vary signifi cantly, either for 
time groups or for individual subjects, over the course of the 
study. Observations 1a, 2a, 3a, 8a, and 15 were made prior to 
the fi rst dose of the day indicated, while observations 1b, 2b, 
3b, and 8b were made 40–60 min after ingesting the second 
1,300 mg dose of calcium formate on the day indicated. The 
sample times “a” and “b” correspond, respectively, to the 
times of trough and peak levels of serum formate following 
single doses (see Ref. 36). The data show no accumulation 
of serum formate with repeated administration of 1,300 mg 
calcium formate three times per day over 14 days.
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ANOVA analysis showed that there were no signifi cant dif-
ferences in amplitude or latency in the six rings in the post-
dosing tests compared to baseline.
In summary, formate did not accumulate in the serum 
with daily dosing, and did not rise signifi cantly above basal 
levels. Physical and ocular examination, laboratory investi-
gation, and electrophysiological assessments all found that 
all subjects remained stable throughout the study period.
Discussion
It is widely recommended that individuals at risk for oste-
oporosis should ingest 1,200–1,500 mg of elemental calcium 
daily in their diet.3,18,19 However, many diets are defi cient 
in calcium, and absorption of calcium decreases with age, 
making supplementation necessary.20 The salt form of cal-
cium can infl uence the rate of calcium absorption.21 Calcium 
formate, Ca(HCO2)2, is a new water-soluble calcium salt with 
potential for use as a dietary calcium supplement.8 One 650 
mg tablet of calcium formate contains 200 mg of elemental 
calcium and 450 mg formate. Calcium formate has a supe-
rior bioavailability profi le compared with other common 
calcium supplements. Being much more soluble than cal-
cium carbonate and much more dissociated in solution than 
calcium citrate, calcium formate demonstrates superior abil-
ity to deliver calcium to the bloodstream after oral admin-
istration and may therefore offer signifi cant advantages as a 
dietary calcium supplement.9
The current study was designed to evaluate the safety 
of oral calcium formate as a calcium supplement, and to 
determine if there is any accumulation of serum formate 
with repeated dosing three times per day over a period of 2 
weeks. As part of the safety assessment, particular empha-
sis was placed on detecting possible untoward effects on the 
visual system, as the retina and optic nerve are the tissues 
most susceptible to adverse effects of sustained high serum 
formate concentrations.11,13,22
Formate is a normal endogenous metabolite in the body. 
It distributes readily throughout total body water and under 
normal conditions appears in plasma or serum at concen-
trations of up to 0.50 mM, refl ecting a balance between the 
production of formate by the catabolism of amino acids and 
other dietary components and the oxidation of formate to 
carbon dioxide by all tissues. Exogenously administered for-
mate is primarily oxidized by the liver to CO2 and exhaled; 
urinary excretion of formate accounts for only 2%–4% of the 
dose.23
Although formate is endogenous to the body, it is toxic if 
very high serum concentrations are achieved and sustained. 
In methanol (wood alcohol) poisoning, formic acid is pro-
duced and ionizes to release hydrogen ions and formate ions. 
Methanol poisoning is characterized by profound systemic 
acidosis, which does not occur with calcium formate inges-
tion as there are no hydrogen ions to release. In methanol-
intoxicated subjects, ocular and systemic toxicity can occur 
following prolonged and substantial elevation of serum for-
mate levels.24 Retinal and vitreous humor formate concentra-
tions closely parallel blood formate concentrations.25 Studies 
in vitro and in methanol-intoxicated rodents have shown 
that formate ion inhibits cytochrome oxidase, the terminal 
electron acceptor of the mitochondrial electron transport 
chain essential for mitochondrial energy production.14,26–28 
This results in depletion of retinal and optic nerve ATP that 
function during the study. These results are supported by 
the stability in the MERG (Fig. 3). Results were analyzed 
by concentric rings emanating from the fovea, comparing 
group results between baseline and two follow-up points, 
as well as comparing individual subject results. Multivariate 
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FIG. 2. Normal full-fi eld electroretinogram results in the 
right eye of subject 1 at Day 8, 45 min after ingestion of the 
second 1,300 mg dose of calcium formate on that day. This 
sampling time corresponds to the expected peak level of for-
mate absorption as noted in Figure 1.
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14 healthy women found that the plasma formate concen-
tration rose quickly but modestly within 30–60 min and 
returning to baseline within <4 h. Thus, the maximum 
serum formate levels following a single large dose of cal-
cium formate were far below toxic levels and were elevated 
only transiently, suggesting no liability for accumulation of 
serum formate from dose to dose.36 No adverse effects were 
noted by any of the subjects in the prior studies.
A major purpose of the present study was to evaluate 
whether the amount of formate absorbed from repeat dos-
ing of calcium formate presented a toxic challenge to the eye 
and other organs. The numerous ocular tests were timed to 
correspond with the peak serum levels of formate. Extensive 
laboratory testing followed other metabolic parameters 
that would indicate abnormal underlying function of major 
organs or an abnormal response to calcium formate inges-
tion. There were no changes from baseline status in the 
subjects’ endocrine, renal, hepatic, respiratory, and hema-
tologic tests. Serum calcium, ionized calcium, and parathy-
roid hormone measured prior to the fi rst dose of the day 
remained stable. Serum formate analyses were performed 
at the screening examination, at baseline, and at trough 
and peak periods for serum formate throughout the 2-week 
study period. There is a basal level of formate in the serum, 
and a known toxic range. In this study, despite the ingestion 
of large doses of calcium formate, at no time did the serum 
reduces the activity of the membrane Na–K ATPase pump, 
leading to loss of conduction of the action potential, damage 
to the myelin sheath, and loss of vision. It also leads to sta-
sis of axoplasmic fl ow that results in intra-axonal swelling 
and optic disc edema.29 Histological studies have confi rmed 
predominant mitochondrial damage.30,31 Optic nerve and 
retinal damage are identifi ed by loss of pupillary response, 
optic nerve edema, retinal edema, and hemorrhages, and are 
corroborated by abnormalities in functional tests including 
visual acuity, color vision, and visual fi eld abnormalities.11 
In animal models and case reports of human toxicity, reduc-
tions in electroretinogram and VEP responses occurred 
with severe and extended blood formate accumulation.13,14 
Therefore, this study included multiple methods to evalu-
ate both optic nerve and retinal function as calcium formate 
was administered over 2 weeks.
Formate is a weak inhibitor of cytochrome oxidase with 
an apparent inhibition constant (Ki) between 5 and 30 mM.12 
To have potential for toxicity, serum formate levels must 
be sustained above 7.0 mM for 24 h.11,22,32,33 Cases of metha-
nol poisoning can achieve serum formate concentrations of 
10–20 mM or more.34 In contrast, peak serum formate lev-
els after oral administration of a very large single oral dose 
of calcium formate (4,550 mg) in human subjects averaged 
0.7 ± 0.07 mM.35 A pharmacokinetic study of a single large 
(3,900 mg) oral dose of calcium formate administered to 
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not identify any toxicity. Therefore, both the subjective and 
objective evaluation of retinal anatomy and retinal function 
found no evidence of toxicity.
There were several instances of nonserious adverse 
events attributed to the study compound. Two individuals 
developed mild transient abdominal cramps that resolved 
spontaneously, one developed a headache on one occasion, 
and another had episodes of diaphoresis. The side effects 
described are common with ingestion of calcium supple-
ments in any form.45 The most common side effect of cal-
cium ingestion is constipation, which did not occur in this 
study.46
This preliminary study demonstrates that calcium for-
mate can be ingested repeatedly in moderately high doses 
with no severe adverse events occurring. Ocular and sys-
temic function as evaluated by numerous parameters 
remained unchanged. Serum formate levels remained near 
basal levels, with no evidence of formate accumulation after 
2 weeks of repeated use three times per day. This fi nding is 
in signifi cant contrast to the accumulation of serum formate 
that characteristically occurs in methanol poisoning. This 
study also demonstrates that exogenous formate is well-tol-
erated when used to promote calcium absorption. Calcium 
formate is highly bioavailable and can therefore be admin-
istered in lower doses. As it is well-tolerated, compliance 
with a calcium supplementation regimen may be improved. 
In view of the critical need to increase the rate of calcium 
supplementation in the population at risk for osteoporosis,47 
it is important to improve the individual’s ability to be com-
pliant with their regimen. This may decrease the morbidity 
associated with osteopenia and osteoporosis. Prior studies 
with calcium formate supplementation have demonstrated 
signifi cantly greater increases in serum calcium concentra-
tion and greater bioavailability than equimolar amounts 
of calcium from supplements based on calcium carbonate 
or calcium citrate. In combination with the lack of formate 
accumulation and the lack of toxicity demonstrated in this 
study, calcium formate may have considerable promise for 
use as a new dietary calcium supplement.
Conclusion
Calcium formate is a novel, highly bioavailable calcium 
salt with potential for use as a dietary calcium supplement. 
Twelve healthy women participated in an ocular and sys-
temic safety study, ingesting 1,300 mg of calcium formate 
three times a day for 2 weeks. The dietary supplement was 
well-tolerated and safe, with no adverse physical, labora-
tory, or electrophysiological fi ndings. Evaluation of retinal 
and optic nerve function included extensive objective test-
ing. The results remained normal throughout the study, 
with no signifi cant change from baseline. Except for mild 
transient increases immediately after dosing, serum formate 
did not accumulate and remained near basal levels. To our 
knowledge, this is the only study of the effects of adminis-
tering formate to human subjects in high doses, repeatedly, 
over 14 days. Since there was no evidence of toxicity in this 
study, and since calcium formate is highly bioavailable, it 
may prove to be a good choice for calcium supplementation 
for maintaining bone integrity. While the absence of seri-
ous adverse effects in this study is encouraging, longer term 
studies with larger groups of subjects representing more 
varied age, health, dietary, and nutritional status are needed 
formate concentration approach the levels required to pro-
duce ocular toxicity. The highest single peak serum concen-
tration observed was 0.83 mM, and such peaks are transient 
due to the rapid metabolism of formate to carbon dioxide. In 
contrast, based on results from cases of methanol poisoning, 
toxicity to the visual system requires prolonged elevation 
above 7 mM. The peak serum levels on day 1 and day 3 were 
higher than the screening serum formate, but were equiva-
lent with the mean baseline serum formate level, obtained 
prior to ingestion of supplement on day 1. The peak serum 
level on day 8 and the fi nal level on day 15 were not signif-
icantly different than screening or baseline levels, demon-
strating a lack of accumulation of formate in the serum.
Formate toxicity, in the setting of methanol poisoning, 
has been associated with optic nerve abnormality and dys-
function, described as edematous or hyperemic optic nerves, 
loss of pupillary refl exes, and extinguished VEP in severe 
cases.29,37 VEP testing can identify signs of toxicity before 
clinical optic neuropathy is evident.38 Over the course of 
this study, the optic nerve appearance remained normal as 
assessed by the examiner and masked graders. Functional 
assessment of pupillary response to light as well as objective 
assessment with VEPs, conducted at times to coincide with 
peak serum formate concentration, remained normal. Visual 
fi elds remained normal, with no signifi cant change in mean 
defect. Similarly, ganglion cell function, evaluated with pat-
tern ERG, remained unchanged throughout the study. There 
was no evidence of a deleterious effect of calcium formate on 
optic nerve anatomy or function.
Dilated retinal examinations were conducted through-
out the study and documentary photographs were obtained. 
Retinal edema was described in many cases in a series of 
323 individuals who ingested methanol-contaminated whis-
key. Other ocular signs included constricted visual fi elds, 
fi xed and dilated pupils, and optic nerve edema. Many of 
these individuals lost their vision.39,40 It is notable that visual 
changes occurred in those with concurrent systemic acido-
sis, an event that cannot occur with calcium formate inges-
tion, even at high doses. The current study identifi ed no 
changes from the normal baseline retinal appearance with 
repeated calcium formate ingestion. Functional assessment 
included best-corrected ETDRS visual acuity and color 
vision testing with the FM-100 Hue test. Interestingly, visual 
acuity improved in both eyes over the course of the study 
with statistical signifi cance from 87.92 ± 5.9 to 90.5 ± 6.5 let-
ters in the right eye and from 89.0 ± 4.0 to 91.4 ± 4.0 letters 
in the left eye (P = 0.007); this is probably due to a learn-
ing effect. Similarly, a slight reduction in the error scores for 
color vision testing would be accounted for by a learning 
effect.
Our objective testing of retinal function included full-
fi eld ERG and multifocal ERG to evaluate photoreceptor, 
bipolar, and Muller cell function. Formate toxicity has been 
associated with a dose-related reduction in the ERG a-wave 
(photoreceptor function) and b-wave (bipolar/Muller cell 
function).14,41,42 Both rod-dominated and cone-mediated 
electroretinogram responses are profoundly attenuated in 
methanol-intoxicated rats. Histopathologic changes were 
apparent in photoreceptors and RPE cells, with evidence 
of inner segment swelling and mitochondrial disrup-
tion.30,40,43,44 This study found no signifi cant changes in the 
ERG over time. MERG results corroborated this, indicating 
that even the isolation of retinal responses into regions did 
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population.
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